Bone turnover and metabolite responses to exercise in people with and without long-duration type 1 diabetes: a case-control study

Guy S Taylor, 1 Othmar Moser, 2 Kieran Smith, 1 Andy Shaw, 1 Jonathan C Y Tang, 3 William D Fraser, 3 Max L Eckstein, 2 Faisal Aziz, 4 Emma J Stevenson, 1 James A Shaw, 5 Daniel J West 1

ABSTRACT

Introduction Exercise acutely alters markers of bone resorption and formation. As risk of fracture is increased in patients with type 1 diabetes, understanding if exercise-induced bone turnover is affected within this population is prudent. We assessed bone turnover responses to acute exercise in individuals with long-duration type 1 diabetes and matched controls.

Research design and methods Participants with type 1 diabetes (n=15; age: 38.7±13.3; glycosylated hemoglobin: 60.5±6.7 mmol/mol; diabetes duration: 19.3±11.4 years) and age-matched, fitness-matched, and body mass index-matched controls (n=15) completed 45 min of incline walking (60% peak oxygen uptake). Blood samples were collected at baseline and immediately, 30 min, and 60 min postexercise. Markers of bone resorption (β-C-terminal cross-linked telopeptide of type 1 collagen, β-CTX) and formation (procollagen type-1 amino-terminal propeptide, P1NP), parathyroid hormone (PTH), phosphate, and calcium (albumin-adjusted and ionized) were measured. Data (mean±SD) were analyzed by a mixed-model analysis of variance.

Results Baseline concentrations of P1NP and β-CTX were comparable between participants with type 1 diabetes and controls. P1NP did not change with exercise (p=0.20) but β-CTX decreased (p<0.001) in both groups, but less so in participants with type 1 diabetes compared with controls (−9.2±3.7%; p=0.02). PTH and phosphate increased immediately postexercise in both groups; only PTH was raised at 30 min postexercise (p<0.001), with no between-group differences (p>0.39). Participants with type 1 diabetes had reduced albumin and ionized calcium at all sample points (p<0.01).

Conclusions Following exercise, participants with type 1 diabetes displayed similar time-course changes in markers of bone formation and associated metabolites, but an attenuated suppression in bone resorption. The reduced albumin and ionized calcium may have implications for future bone health. Further investigation of the interactions between type 1 diabetes, differing modalities and intensities of exercise, and bone health is warranted.

INTRODUCTION

Osteoporosis and fractures are common complications of type 1 diabetes, with a onefold to twofold increased risk of fracture at any skeletal site. 1, 2 Long-term type 1 diabetes is associated with deficits in bone density, structure, microarchitecture, and turnover. 3, 4 Exposure to hyperglycemia and oxidative stress, 5, 6 elevated sclerostin, 7 insulinopenia and decreased gastrointestinal hormones, and chronic inflammation...
Pathophysiology/complications

are all potential drivers. At the time of clinical manifestation of type 1 diabetes, around 80% of β-cell mass is already lost. In parallel, lower levels of bone formation and resorption markers, including osteocalcin, procollagen type I amino-terminal propeptide (P1NP), and β-C-terminal cross-linked telopeptide of type 1 collagen (β-CTX), are observed. In addition to bone remodeling being impaired in recently diagnosed individuals, a diagnosis before or during puberty and poor glycemic control are further associated with reduced bone turnover and bone mineral density.

Human bone is continuously undergoing resorption, its breakdown by osteoclasts releasing calcium and phosphate into the circulation, and formation, a process by which osteoblasts lay down new bone material. Osteocytes, the most abundant bone cell phenotype that regulates bone formation and initiates bone resorption, control bone remodeling by responding to mechanical strain. After a certain age, varying between individuals, the rate of bone resorption starts to exceed the rate of bone formation, resulting in net bone loss. As the population of individuals with type 1 diabetes ages, so does the rate of diabetes-induced osteoporotic fractures. In combination with the increased life expectancy seen during the past century due to improvements in management and survival in type 1 diabetes, interventions are needed to reduce the occurrence of osteoporotic fractures in this growing population of older individuals with type 1 diabetes.

Regular exercise should be an integral part of modern diabetes management. Structured training and physical activity have the potential to improve glycemic control, reduce inflammation, lower the demand for exogenous insulin, and improve quality of life. Exercise training has been shown to increase bone formation and decrease bone resorption in healthy and disease states; thus, exercise interventions may be able to improve bone health in those with type 1 diabetes. While endurance exercise programs have not appeared to benefit bone health in diabetic rats, there is limited evidence of the effects of exercise on bone turnover in humans with type 1 diabetes. Previous studies have demonstrated that 9-month weight bearing and 3-month aerobic exercise interventions were successful at increasing bone mineral density and altering the circulating levels of biochemical bone turnover markers in children and adolescents with type 1 diabetes, respectively. However, little is known on the acute effects of physical activity on the markers of bone turnover in individuals with type 1 diabetes.

As over 90% of the organic matrix of bone is type 1 collagen, many of the commonly used markers of bone turnover relate to its synthesis or degradation. These include P1NP, cleaved during the synthesis of type 1 collagen and thus a marker of bone formation, and β-CTX, a product of the degradation of type 1 collagen and thus a marker of bone resorption. As bone resorption and formation are tightly coupled, high levels of either bone resorption markers or bone formation markers signify a high bone turnover rate. Single exercise bouts have been shown to alter the circulating concentrations of P1NP and β-CTX, parathyroid hormone (PTH), a regulator of bone remodeling, and related metabolites (calcium and phosphate) in young and old people free from disease. Given the deficits observed in bone turnover within patients with type 1 diabetes, it is important to understand if bone turnover response to acute exercise is comparable with those without diabetes and what clinical factors are driving any abnormalities.

Studies investigating the bone response to exercise in healthy individuals have mainly been carried out in fasted conditions, often involving intense exercise. As moderate intensity and duration of aerobic exercise is the most commonly advocated physical activity by the American Diabetes Association (ADA), and a carbohyd late snack prior to exercise is often required to meet the international consensus advice on pre-exercise blood glucose concentration to reduce the risk of exercise-induced hypoglycemia, it is unclear how applicable this research is to the type 1 diabetes population. Additionally, the challenges of glycemic management and various comorbidities can make performing intense exercise unrealistic for individuals with type 1 diabetes.

The aim of the present study was to investigate bone turnover response to moderate-intensity, continuous physical exercise in people with type 1 diabetes compared with healthy controls, replicating real-world exercise practices of this population.

METHODS

The trial was registered at the ISRCTN registry (http://www.isrctn.com/ISRCTN10346879). Fully informed participants gave written consent before any trial-related activities.

Participants

The eligibility criteria for the type 1 diabetes group comprised age between 18 and 65 years (inclusive), clinical diagnosis of type 1 diabetes (weight loss, ketotic, hyperglycemic and insulin initiation at diagnosis) at least 3 years before enrollment, glycosylated hemoglobin (HbA1c) <10.0% (86 mmol/mol), and absence of clinically diagnosed diabetes-related microvascular/macrovascular complications (apart from background retinopathy), recent fractures, or abnormal estimated glomerular filtration rate. A minimum duration of diabetes of 3 years was used to allow a clear gap from the approximate 2-year point often referred to as the ‘honeymoon period’. Participants had to have stable multiple daily injection (MDI) or continuous subcutaneous insulin infusion (CSII) regimen without changes over the preceding 6 months. The healthy control group was matched in gender, age, cardiorespiratory fitness (peak oxygen uptake, VO2peak) and anthropometry. Participants with type 1 diabetes were recruited from the Newcastle Diabetes Centre by posters and clinicians passing the
details of interested patients to the study team. The healthy control group were recruited from Newcastle University using posters and emailing lists.

Screening visit
Participants attended the Newcastle National Institute for Health Research Clinical Research Facility on two separate occasions. First, participants attended for a screening visit to determine eligibility and for medical assessment and resting ECG. Eligible participants then completed a maximal graded walking to running exercise treadmill test based on the Bruce protocol, as previously described by our group. Participants with type 1 diabetes had their capillary blood glucose concentration measured prior to the maximal test. If blood glucose was below 7 mmol/L (126 mg/dL), then 10–30 g of carbohydrate was orally administered via a glucose drink. If blood glucose was above 15 mmol/L (270 mg/dL), the test was rescheduled. Breath-by-breath respiratory parameters (MetaLyzer 3B, Cortex, Leipzig, Germany) and heart rate (H10, Polar, Kempele, Finland) were continuously recorded throughout the maximal test. VO2peak was determined by the average oxygen consumption measured over the 30 s prior to test termination.

Trial visits
Participants returned to the laboratory at least 1 week after their screening visit and following an overnight fast (from 22:00). Participants were instructed to maintain their normal basal insulin regimen. If they had a hypoglycemic event overnight prior to the study visit, the visit was rearranged. On arrival at ~08:30, the non-dominant arm of each participant was cannulated. One 10 mL EDTA (Becton, Dickinson and Company, New Jersey, USA) and two serum separation tubes (SST II Advance, Becton, Dickinson and Company) were collected at all time points (baseline, immediately postexercise (0 min post), 30 min post and 60 min post). An additional 4 mL EDTA vacutainer was drawn at baseline for HbA1c analysis. The EDTA and one SST vacutainer were centrifuged for 10 min at 1500 g at 4°C; serum and plasma were aliquoted and stored at −80°C at the Faculty of Medical Sciences Biobank Facility.

Participants ate a carbohydrate snack (Belvita Soft Bakes Chocolate Chip, Mondelēz International, USA), providing 204 kcal including 31 g of carbohydrate, immediately after baseline blood tests and remained rested for 30 min before starting the trial protocol. After assessment for a safe blood glucose level from 7 mmol/L (126 mg/dL) to 12 mmol/L (216 mg/dL), participants completed 45 min of steady-state incline walking on a treadmill with exercise intensity set at 60% of VO2peak. If blood glucose dropped below 7 mmol/L during exercise, the participants with type 1 diabetes were given an additional 10 g of carbohydrate. Individuals’ breath-by-breath respiratory parameters (MetaLyzer 3B, Cortex) and heart rates (H10, Polar) were continuously recorded throughout the exercise session. Immediately after cessation of exercise, a further blood sample was collected, before participants were seated. Further venous samples were collected at 30 min and 60 min postexercise, after which the cannula was removed and the participant was discharged from the laboratory if the glucose concentration was >3.9 mmol/L (70 mg/dL).

Blood sample analysis
Ionized calcium concentrations and HbA1c were analyzed by routine hospital clinical biochemistry (Royal Victoria Infirmary, Newcastle upon Tyne). EDTA plasma concentrations of β-CTx, PINP, and PTH were measured using electrochemiluminescence immunoassay on a Cobas e601 analyzer (Roche Diagnostics, Germany), with interassay coefficient of variation (CV) ≤3% within the analytical range of 0.2–1.5 µg/L, 20–600 µg/L and 0.127–530 pmol/L, respectively. Serum total calcium, phosphate, and albumin were measured using standard spectrophotometric methods performed on a Roche Cobas c501 analyzer, with interassay CV ≤2% within the analytical range of 0.05–5.00 mmol/L, 0.10–6.46 mmol/L and 10–70 g/L, respectively. Serum albumin values were used to calculate the albumin-adjusted calcium (CaAlb) using the following equation: CaAlb = (0.8 × [albumin−4])+[total calcium]. The analyses took place at the Bioanalytical Facility (University of East Anglia, UK).

Statistical analysis
Participants’ characteristics were tabulated as frequencies and percentages (%) for qualitative variables and means±SD for quantitative variables. A mixed-model (time×group), repeated-measures analysis of variance with Tukey post-hoc analysis was performed for absolute values and baseline-adjusted percentage change values (1) to assess the effect of moderate-intensity physical exercise on bone turnover markers over time; (2) to compare the overall effect of exercise on bone turnover markers in people with type 1 diabetes and healthy controls; and (3) to examine the difference in the effect of exercise on bone turnover markers over time between people with type 1 diabetes and healthy individuals. Resting counts were assessed by independent t-test. Data were assessed for normality and outliers by Shapiro-Wilk test and boxplots, with skewed data transformed. Relationships were assessed by Pearson’s or Spearman’s correlation.

Sample size was estimated from available data. In order to detect a difference of at least 5% in the changes in β-CTx, PINP, and PTH with exercise between groups, a sample size of 15 (excluding dropout) per group was needed to test the null hypothesis that the population means are equal, with a probability of 0.8. The type I error associated with this test is 0.05. Data are presented as means±SD. A p value <0.05 was considered statistically significant.

RESULTS
Fifteen people with type 1 diabetes (age: 38.7±13.3; diabetes duration: 19.3±11.4 years; method of control:
Pathophysiology/complications

Table 1 Characteristics of participants at baseline

| Variable         | Type 1 diabetes (n=15) | Control (n=15) | P value |
|------------------|------------------------|----------------|---------|
| Age (years)      | 38.7±13.3              | 41.6±12.4      | 0.546   |
| Gender, n (%)    |                        |                |         |
| Female           | 7 (46.7)               | 7 (46.7)       | –       |
| Male             | 8 (53.3)               | 8 (53.3)       |         |
| Ethnicity, n (%) |                        |                |         |
| White British    | 14 (93.3)              | 14 (93.3)      |         |
| Indian           | 1 (6.7)                | 0 (0)          |         |
| African          | 0 (0)                  | 1 (6.7)        |         |
| BMI (kg/m²)      | 24.2±2.1               | 23.9±3.2       | 0.775   |
| VO₂peak (mL/kg/min) | 39.1±9.3           | 44.7±11.6      | 0.153   |
| HbA1c (mmol/mol) | 60.5±6.7               | 34.0±2.2       | <0.001  |
| HbA1c range (mmol/mol) | 53–74            | 30–39          |         |

Data are presented as mean±SD. Independent sample t-tests were performed to compare the quantitative variables between groups. BMI, body mass index; HbA1c, glycosylated hemoglobin; VO₂peak, body weight relativized peak oxygen uptake.

MDI n=6 and CSII n=9 and age-matched, fitness-matched, anthropometric-matched and gender-matched controls were included in this case–control study (table 1). No participant reported having a dietary pattern or restrictions that would suggest an abnormal habitual dietary calcium intake. All participants completed the protocol without any adverse events or missed samples. The two groups exercised at a matched intensity of their VO₂peak (type 1 diabetes: 60.4%±4.4% vs control: 60.8%±5.1%; p=0.734).

The absolute data are presented in figure 1, with percentage change from baseline plotted in figure 2. The p values for the main effects of time, group, and group*time interaction are included with each parameter in figures 1 and 2. Baseline concentrations for all markers are presented in table 2.

There were main effects of time for β-CTx, PTH, albumin, phosphate, and calcium (figure 1). There were group effects for albumin and ionized calcium, with controls having higher concentrations of both measures at rest and at all time points, when compared with type 1 diabetes (figure 1D,1H and table 2). There were time*condition effects for β-CTx only, with the control group only having reduced concentration at 60 min compared with baseline (figure 1A). When expressed as a percentage change from baseline, there were time*group interactions for β-CTx, with reduction in concentrations of 16%±12% vs 25%±8% in the type 1 diabetes group and controls, respectively (p=0.018; figure 2A).

HbA1c was inversely related to albumin (r=−0.657, p<0.001) in the fasted state. VO₂peak was related to fasting levels of β-CTx (r=0.478, p=0.008) and P1NP (r=0.417, p=0.022). Duration of type 1 diabetes was inversely associated with fasted concentrations of albumin (r=−0.636, p<0.001) and β-CTx (r=−0.535, p=0.045). Within the type 1 diabetes group, neither HbA1c, body mass index nor VO₂peak predicted any percentage change with exercise in the measured variables (p>0.05). Older age and longer duration of diabetes were associated with greater decrease in albumin (r=−0.757, p=0.001; r=−0.635, p=0.011), calcium (r=−0.764, p=0.001; r=−0.574, p=0.025) and adjusted calcium (r=−0.748, p=0.001; r=−0.555, p=0.032) at 30 min postexercise, respectively.

DISCUSSION

The aim of the present study was to assess whether bone turnover response to acute exercise in type 1 diabetes differs compared with that in matched controls free from diabetes. Previous research has largely studied bone turnover response to acute exercise in healthy individuals. This is the first study, to the best of our knowledge, to assess this acute response in humans with type 1 diabetes, with previous research having been carried out in diabetic rat models or exploring exercise training over several months in children or adolescents with type 1 diabetes. The key findings were that (1) baseline P1NP concentrations were comparable between groups and unaffected by moderate-intensity exercise, (2) baseline β-CTx concentrations were also comparable between groups and fell with exercise (more so in controls), (3) PTH and phosphate levels both rose with exercise, with no difference between groups, and (4) those with type 1 diabetes had overall lower levels of albumin and ionized calcium. Our data provide a clinically relevant insight into the interaction.

In the present study moderate-intensity exercise caused no change in P1NP, a fall in β-CTx, and a rise in PTH in both participants with type 1 diabetes and controls. While there were no statistically significant differences in resting concentration of P1NP and β-CTx in the current study (table 2), the baseline β-CTx concentration of 0.8 µg/L lower in type 1 diabetes group compared with the controls is similar to the significantly reduced β-CTx levels (−0.10 µg/L, 95% CI −0.18 to −0.01 µg/L) seen in a recent meta-analysis. While there is lack of studies investigating P1NP in type 1 diabetes specifically, the resting concentration in this study (−9.82 µg/L in the type 1 diabetes group in comparison with the controls) reduced by a similar amount as individuals with type 2 diabetes compared with controls.

Procollagen type-1 amino-terminal propeptide

Moderate-intensity exercise training has previously been demonstrated to alter resting P1NP concentration. Indeed, Adami et al found that P1NP increased after an exercise program of a month’s duration in premenopausal women, which was associated with increased bone mineral density. In comparison, Maggio et al did not find a significant change in P1NP in children either with or without type 1 diabetes completing 9 months of two 90 min plyometric exercise sessions per week compared with non-exercising controls. This is despite the type 1 diabetes group having significantly
Figure 1 Absolute change in β-CTX (A), P1NP (B), PTH (C), albumin (D), phosphate (E), calcium (F), adjusted calcium (G) and ionized calcium (H) in response to a single bout of moderate-intensity exercise in those with type 1 diabetes and healthy controls. Blood samples were collected 30 min before exercise (baseline), and immediately (0 min post), 30 min, and 60 min after cessation of exercise. *Significant main effect of group differences. △Significant main effect of time difference from baseline. *| Significant group differences at time point. The green triangle denotes significant time difference from baseline in the type 1 diabetes group, while the blue triangle denotes significant time difference from baseline in the control group. β-CTX, β-C-terminal cross-linked telopeptide of type 1 collagen; P1NP, procollagen type-1 amino-terminal propeptide; PTH, parathyroid hormone.
Figure 2  Percentage change from baseline of $\beta$-CTx (A), P1NP (B), PTH (C), albumin (D), phosphate (E), calcium (F), adjusted calcium (G) and ionized calcium (H) in response to a single bout of moderate-intensity exercise in those with type 1 diabetes and healthy controls. Blood samples were collected 30 min before exercise (baseline), and immediately (0 min post), 30 min, and 60 min after cessation of exercise. *Significant main effect of group differences. $\Delta$Significant main effect of time difference from baseline. $|$Significant group differences at time point. The green triangle denotes significant time difference from baseline in the type 1 diabetes group, while the blue triangle denotes significant time difference from baseline in the control group. $\beta$-CTx, $\beta$-C-terminal cross-linked telopeptide of type 1 collagen; P1NP, procollagen type-1 amino-terminal propeptide; PTH, parathyroid hormone.
lower resting concentration. In comparison, Elhabashy et al.30 demonstrated that P1NP significantly increased by 40% after 3 months of three 60 min aerobic exercise per week in adolescents with type 1 diabetes. However, without a control group, it is unclear if this was a normal response. While both studies found increases in bone mineral density, differences in biochemical markers of bone turnover are likely due to differing populations and the frequency and type of exercise used. The acute P1NP response to exercise is less clear in biochemical markers of bone turnover are likely due to differing populations and the frequency and type of exercise used.

The acute increase in P1NP levels when healthy men ran at 55% VO2peak high-intensity interval running or running at 75% VO2max until exhaustion. It is possible that our protocol was not strenuous enough to induce an increase in P1NP, or that we did not take measurements over a sufficient time period to detect such a rise. Nevertheless, Scott et al.30 reported an acute increase in P1NP levels when healthy men ran at 55%, 65%, and 75% of VO2max, but there was no effect of exercise intensity on P1NP response. It is possible the amount of mechanical strain, rather than exercise intensity, is key to inducing P1NP secretion. It would thus be interesting to repeat our study using a running protocol.

β-C-terminal cross-linked telopeptide of type 1 collagen

The fall in β-CTX observed implies that there was a lower rate of bone resorption at the end of exercise. Scott et al.30 also found that β-CTX fell in their study both during and for 3 hours after treadmill running at 55% and 65% of VO2max. Other studies have however observed β-CTX to increase with acute exercise or be unaffected. Indeed, Guillemant et al.30 found elevated β-CTX levels in male athletes after 60 min of cycling at 80% VO2max. The acute response of β-CTX to exercise may depend on exercise type, duration, and intensity, as well as the individual’s age, sex, and habitual loading of bones.30 Importantly, prior consumption of calcium or carbohydrate, as administered in this study, appears to result in greater suppression of β-CTX during and after exercise, compared with fasting conditions.30 Additionally, β-CTX is influenced by the circadian rhythm, peaking at 05:30, with nadir at 13:30.41 After 9 months of exercise training, Maggio et al.30 found both children with and without type 1 diabetes had reduced levels of β-CTX; however, the reduction was less than both the type 1 diabetes and control groups who did not go through the exercise intervention. In the present study baseline β-CTX levels were (not significantly) lower, and when adjusted for baseline the percentage decrease with exercise in those with type 1 diabetes was less than in the controls. This suggests that bone in type 1 diabetes may have lower basal rate of turnover and remodels less in response to a bout of fed moderate-intensity exercise. Further investigation is needed to understand if the acute differences seen in β-CTX around exercise are clinically relevant in the long term.

Parathyroid hormone

The exercise-induced rise in PTH that we observed was in keeping with previous work30 and was likely due mainly to a fall in ionized calcium.36 As with P1NP and β-CTX, there may be an exercise intensity threshold for PTH secretion in endurance exercise.30 While high basal levels of PTH have a catabolic effect, intermittent PTH secretion, such as that observed here, has an anabolic effect on bone,38 stimulating proliferation and inhibiting apoptosis in osteoblasts.30 It is difficult to prove without a longer-term study, but tempting to suggest, that our exercise protocol had a positive net effect on bone turnover in both the healthy controls and the type 1 diabetes group, even if the β-CTX resorption response may be slightly attenuated in the latter.

Bone turnover-associated metabolites

In the current study, those with type 1 diabetes had lower absolute levels of albumin compared with controls. A longer duration of type 1 diabetes and poorer glycemic control were also both associated with lower fasted levels of albumin. This is un surprising, as hepatic albumin production is stimulated by insulin and is therefore decreased in type 1 diabetes.42 We also found lower levels of ionized calcium in participants with type 1 diabetes compared with controls. This has been reported previously, as a result of reduced intestinal absorption and increased urinary excretion of calcium, as well as the dysregulated PTH secretion observed in type 1 diabetes.43 While still within normal ranges, the lower levels of albumin and ionized calcium in the type 1 diabetes group compared with the age-matched, gender-matched, anthropometry-matched and cardiorespiratory fitness-matched controls may be an indicator of

**Table 2** Resting concentrations of biochemical markers of bone turnover

| Variable          | Type 1 diabetes (n=15) | Control (n=15) | P value |
|-------------------|------------------------|----------------|---------|
| β-CTX (μg/L)      | 0.32±0.17              | 0.40±0.16      | 0.174   |
| P1NP (μg/L)       | 44.58±22.06            | 54.40±25.57    | 0.235   |
| PTH (pmol/L)      | 2.37±1.03              | 2.89±0.90      | 0.149   |
| Albumin (g/L)     | 39.44±2.03             | 43.11±2.47     | <0.001  |
| Phosphate (mmol/L)| 1.05±0.19              | 1.02±0.18      | 0.675   |
| Calcium (mmol/L)  | 2.26±0.08              | 2.27±0.08      | 0.652   |
| Adjusted calcium  | 2.27±0.08              | 2.24±0.07      | 0.394   |
| Ionized calcium   | 1.16±0.04              | 1.20±0.01      | 0.011   |

Data are presented as means±SD. Independent sample t-tests were performed to compare the quantitative variables between groups.
future clinical implications, such as edema formation, neuromuscular irritability, and cardiac complications of hypocalcemia. In the present study the response of calcium, ionized calcium, adjusted calcium, and albumin to exercise was in line with previous studies and the same in both groups: falling 30 min postexercise and returning to baseline by 60 min post. The response of phosphate to exercise was also comparable between groups: increasing immediately after and returning to baseline by 30 min postexercise. This reflects previous studies carried out in healthy individuals. As inorganic phosphate is a major component of bone mineral, its postexercise rise may be evidence of bone resorption having occurred during the protocol. In type 1 diabetes, calcium, albumin, and phosphate homeostasis is deranged, and yet we found that moderate-intensity exercise could still induce appropriate changes in their profiles. Bone in type 1 diabetes is thus seemingly still responsive to acute exercise.

Type 1 diabetes and bone health
As healthcare continues to improve, people with type 1 diabetes are living longer. As most are diagnosed during their youth/young adulthood, they are exposed for many years to the effects of hyperglycemia and do not fully benefit from the anabolic effects of endogenous insulin on bone during the period of peak acquisition of bone mass. Chronic hyperglycemia results in the formation of advanced glycation end products, which suppress bone formation, increase bone brittleness and impair fracture healing. Long-term hyperglycemia also compromises bone vasculature, resulting in decreased bone remodeling. This results in poor bone mineral density and quality, and a high rate of osteoporotic fractures in an aging type 1 diabetes population. This ultimately may lead to increased morbidity and mortality. Exercise can improve glycemic control and sensitivity to exogenous insulin, and was shown to reduce the risk of falls and fractures in the elderly in a Cochrane review, a complication that individuals with type 1 diabetes are highly vulnerable to. Yet exercise rates are lower in those with type 1 diabetes, with reasons including fear of hypoglycemia, uncertainty about how to control blood sugars around exercise, and diabetes complications. Our data show that those with type 1 diabetes still benefit from the acute effects of exercise on bone turnover. This further underlines the benefits of exercise in type 1 diabetes and that it may be a viable strategy to reducing the osteoporotic fracture rate in older individuals with type 1 diabetes.

Strengths, limitations and future work
Comparing our exercising type 1 diabetes group with a control group who rested, or having participants perform the protocol in a fasted state, would have provided further useful data. However, we were most interested in studying bone turnover response in type 1 diabetes to exercise under real-world conditions: moderate-intensity, moderate-duration exercise as recommended by the ADA, while following international guidelines for glycemic management around exercise. We believe this makes the research more generalizable and is a strength of this study. A limitation of the current study was the blood samples not being taken during exercise or beyond 1 hour afterwards, which would have given us information on any mid-exercise or delayed postexercise response of bone turnover markers. Additionally, measuring bone mineral density at rest would have been interesting to explore if this was associated with bone turnover response to acute exercise. As baseline samples were fasted, changes in bone turnover markers likely have been impacted by consumption of a carbohydrate snack. While our type 1 diabetes group had a range of ages and HbA1c levels, our study was not designed to explore the influence of age and HbA1c on bone turnover response to exercise. Future studies should explore how individuals with differing HbA1c respond to exercise in order to translate this research to the wider type 1 diabetes population. As individuals with type 1 diabetes are at increased risk of fractures due to trabecular and cortical bone density defects, understanding if exercise improves bone quality at sites most at risk of fractures would be beneficial. Further understanding how clinical factors, such as age and sex differences, influence bone turnover response to exercise would also be beneficial. Indeed, as C peptide infusion improved bone quality in a type 1 diabetic rat model and endogenous C peptide secretion partially predicts postexercise glycemic control, residual β-cell function may influence bone turnover in individuals with type 1 diabetes.

CONCLUSION
We present novel data on the response of bone turnover markers to acute exercise in type 1 diabetes. While bone remodeling is dysregulated in type 1 diabetes, we found fed moderate-intensity walking to have a similarly positive impact on biochemical markers of bone turnover in those with type 1 diabetes compared with controls, evidenced by the rise in PTH and the fall in β-CTX. Studies carried out in healthy individuals suggest that exercise protocols that maximize mechanical strain on the bone may be superior for bone health and that commencing exercise at a young age is important. Further research should aim to decipher the optimal exercise type, duration, and intensity to maximize bone turnover in the long term in type 1 diabetes. This will be key to reducing the incidence of fractures and osteoporosis in this patient group, and ultimately improving morbidity and mortality.
REFERENCES

1. Sellermeyer DE, Civitelli R, Hofbauer LC, et al. Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes. Diabetes 2016;65:1757–66.
2. Wang H, Ba Y, Xing Q, et al. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open 2019;9:e024067.
3. Weber DR, Schwartz G. Epidemiology of skeletal health in type 1 diabetes. Curr Osteoporos Rep 2016;14:327–36.
4. Hygum K, Sarup-Linde J, Harsløf T, et al. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. Eur J Endocrinol 2017;176:R137–57.
5. Sarup-Linde J, Lykkeboe S, Gregersen S, et al. Differences in biochemical bone markers by diabetes type and the impact of glucose. Bone 2016;83:140–55.
6. Sarup-Linde J, Hygum K, Harsløf T, et al. Type 1 diabetes and bone fragility: links and risks. Diabetes Metab Syndr Obes 2019;12:2539–47.
7. Hough FS, Pierroz DD, Cooper C, et al. Mechanisms in endocrinology: mechanisms and evaluation of bone fragility in type 1 diabetes mellitus. Eur J Endocrinol 2016;174:R127–38.
8. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965;14:619–33.
9. Leete P, Wilcox A, Krogvold L, et al. Differential insulin profiles determine the extent of β-cell destruction and the age at onset of type 1 diabetes. Diabetes 2016;65:1362–9.
10. Maggio ABR, Ferrari S, Kraenzlin M, et al. Decreased bone turnover in children and adolescents with well controlled type 1 diabetes. J Pediatr Endocrinol Metab 2010;23:897–707.
11. Fuusager GB, Christensen HT, Milandt N, et al. Glycemic control and bone mineral density in children and adolescents with type 1 diabetes. Pediatr Diabetes 2019;20:629–36.
12. Moerman EJ, Teng K, Lipschitz DA, et al. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γalpha2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004;3:379–89.
13. Yuan Y, Chen X, Zhang L, et al. The roles of exercise in bone remodeling and in prevention and treatment of osteoporosis. Prog Biophys Mol Biol 2016;122:122–30.
14. Livingstone SJ, Levin D, Lucker HO, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA 2015;313:37–44.
15. Rawshani A, Rawshani A, Franzen S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017;376:1407–18.
16. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American diabetes association. Diabetes Care 2016;39:2065–79.
17. Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol 2017;5:377–90.
18. Chimen M, Kennedy A, Nirantharakumar K, et al. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia 2012;55:542–51.
19. Qi Z, Liu W, Lu J. The mechanisms underlying the beneficial effects of exercise on bone remodeling: roles of bone-derived cytokines and microRNAs. Prog Biophys Mol Biol 2016;122:131–9.
20. Verhaeghe J, Thomsen JS, van Bree R, et al. Effects of exercise and disuse on bone remodeling, bone mass, and biomechanical competence in spontaneously diabetic female rats. Bone 2000;27:249–56.
21. Hazell TJ, Olver TD, Kowalchuk H, et al. Aerobic endurance training does not protect bone against poorly controlled type 1 diabetes in young adult rats. Calcif Tissue Int 2017;100:374–81.
22. Maggio ABR, Rizzoli RO, Marchand LM, et al. Physical activity increases bone mineral density in children with type 1 diabetes. Med Sci Sports Exerc 2012;44:1206–11.
23. Elhabashy SA, Said OM, Agahy MH, et al. Effect of physical activity on bone density and remodeling in Egyptian type 1 diabetic osteopenic adolescents. Diabetol Metab Syndr 2011;3:1–6.
24. Shetty S, Kapoor N, Bondu JD, et al. Bone turnover markers: emerging tool in the management of osteoporosis. Indian J Endocrinol Metab 2016;20:846.
25. Malimoun L, Sultan C. Effects of physical activity on bone remodeling. Biomed Res Int 2011;60:373–88.
26. Bouassida I, Latriri I, Bouassida S, et al. Parathyroid hormone and physical exercise: a brief review. J Sports Sci Med 2006;5:367–74.
27. Gombos GC, Bajsz V, Pék E, et al. Direct effects of physical training on markers of bone metabolism and serum sclerostin concentrations in older adults with low bone mass. BMC Musculoskelet Disord 2016;17:254.
28. Rantalanile T, Heinonen A, Linnamo V, et al. Short-term bone biochemical response to a single bout of high-intensity exercise. J Sports Sci Med 2009;8:553–9.
29. Guillermo J, Accarie C, Peres G, et al. Acute effects of an oral calcium load on markers of bone metabolism during endurance cycling exercise in male athletes. Calcif Tissue Int 2004:74:407–14.
30. Scott JPR, Sale C, Greeves JP, et al. The role of exercise intensity in the bone metabolic response to an acute bout of weight-bearing exercise. J Appl Physiol 2011;110:423–32.
31. Schölin A, Berne C, Schwarz E, et al. Factors predicting clinical remission in adult patients with type 1 diabetes. J Intern Med 1999;245:155–62.
32. Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and anthropometric assessment of functional aerobic impairment in young adult rats. Calcif Tissue Int 2004;74:407–14.
33. Taylor GS, Smith K, Capper TE, et al. Postexercise glycemic control in type 1 diabetes is associated with residual β-cell function. Diabetes Care 2020;43:2362–70.
34. Moser O, Eckstein ML, Mueller A, et al. Pre-exercise blood glucose levels determine the amount of orally administered carbohydrates during physical exercise in individuals with type 1 diabetes—a randomized cross-over trial. Nutrients 2019;11:1287.
Pathophysiology/complications

35 Townsend R, Elliott-Sale KJ, Currell K, et al. The effect of postexercise carbohydrate and protein ingestion on bone metabolism. Med Sci Sports Exerc 2017;49:1209–18.

36 Townsend R, Elliott-Sale KJ, Pinto AJ, et al. Parathyroid hormone secretion is controlled by both ionized calcium and phosphate during exercise and recovery in men. J Clin Endocrinol Metab 2016;101:3231–9.

37 Adami S, Gatti D, Viapiana O, et al. Physical activity and bone turnover markers: a cross-sectional and a longitudinal study. Calcif Tissue Int 2008;83:388–92.

38 Hammond KM, Sale C, Fraser W, et al. Post-exercise carbohydrate and energy availability induce independent effects on skeletal muscle cell signalling and bone turnover: implications for training adaptation. J Physiol 2019;597:4779–96.

39 Frost HM. On our age-related bone loss: insights from a new paradigm. J Bone Miner Res 1997;12:1539–46.

40 Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000;11:S30–44.

41 Swanson C, Shea SA, Wolfe P, et al. 24-hour profile of serum sclerostin and its association with bone biomarkers in men. Osteoporos Int 2017;28:3205–13.

42 Chen Q, Lu M, Monks BR, et al. Insulin is required to maintain albumin expression by inhibiting forkhead box O1 protein. J Biol Chem 2016;291:2371–8.

43 Wongdee K, Krishnamra N, Charoenphandhu N. Derangement of calcium metabolism in diabetes mellitus: negative outcome from the synergy between impaired bone turnover and intestinal calcium absorption. J Physiol Sci 2017;67:71–81.

44 Maimoun L, Manetta J, Coute I, et al. The intensity level of physical exercise and the bone metabolism response. Int J Sports Med 2006;27:105–11.

45 Maahas DM, West NA, Lawrence JM, et al. Epidemiology of type 1 diabetes. Endocr Rev Clin North Am 2010;39:481–97.

46 Henderson S, Ibe I, Cahill S, et al. Bone quality and fracture-healing in type-1 and type-2 diabetes mellitus. J Bone Joint Surg Am 2019;101:1399–410.

47 Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2012:CD007146.

48 Shah VN, Wu M, Foster N, et al. Severe hypoglycemia is associated with high risk for falls in adults with type-1 diabetes. Arch Osteoporos 2018;13:66.

49 Maurotti S, Russo C, Musolino V, et al. Effects of C-peptide replacement therapy on bone microarchitecture parameters in streptozotocin-diabetic rats. Calcif Tissue Int 2020;107:266–80.

50 Boudenot A, Achiou Z, Portier H. Does running strengthen bone? Appl Physiol Nutr Metab 2015;40:1309–12.